Standard BioTools Inc. Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination
Standard BioTools Inc. (LAB) reported Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination of $30.42 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination · last filed 2026-03-16
- Standard BioTools Inc. contract with customer, liability, increase (decrease) for contract acquired in business combination for the quarter ending 2024-12-31 was -$3.77M.
- Standard BioTools Inc. contract with customer, liability, increase (decrease) for contract acquired in business combination for the quarter ending 2024-09-30 was $0.00.
- Standard BioTools Inc. contract with customer, liability, increase (decrease) for contract acquired in business combination for the quarter ending 2024-06-30 was $0.00.
- Standard BioTools Inc. contract with customer, liability, increase (decrease) for contract acquired in business combination for the quarter ending 2024-03-31 was $34.19M.
- Standard BioTools Inc. contract with customer, liability, increase (decrease) for contract acquired in business combination for fiscal 2024 was $30.42M.
| Period end | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 3 month | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 6 month | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 9 month | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 12 month | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | -$3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$3.77M derived: sum of 2 quarters · filed 2026-03-16 | -$3.77M derived: sum of 3 quarters · filed 2026-03-16 | $30.42M 10-K · filed 2026-03-16 | $34.61M 10-K · filed 2025-03-11 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $34.19M 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $34.19M 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $34.19M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |